Logo image of GNPX

GENPREX INC (GNPX) Stock Fundamental Analysis

USA - NASDAQ:GNPX - US3724462037 - Common Stock

0.2023 USD
0 (-0.98%)
Last: 10/7/2025, 4:38:04 PM
0.2049 USD
+0 (+1.29%)
After Hours: 10/7/2025, 4:38:04 PM
Fundamental Rating

2

Overall GNPX gets a fundamental rating of 2 out of 10. We evaluated GNPX against 536 industry peers in the Biotechnology industry. GNPX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. GNPX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

GNPX had negative earnings in the past year.
In the past year GNPX has reported a negative cash flow from operations.
GNPX had negative earnings in each of the past 5 years.
In the past 5 years GNPX always reported negative operating cash flow.
GNPX Yearly Net Income VS EBIT VS OCF VS FCFGNPX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

Looking at the Return On Assets, with a value of -518.59%, GNPX is doing worse than 96.64% of the companies in the same industry.
Looking at the Return On Equity, with a value of -1320.11%, GNPX is doing worse than 82.28% of the companies in the same industry.
Industry RankSector Rank
ROA -518.59%
ROE -1320.11%
ROIC N/A
ROA(3y)-300.81%
ROA(5y)-201.57%
ROE(3y)-614.27%
ROE(5y)-390.18%
ROIC(3y)N/A
ROIC(5y)N/A
GNPX Yearly ROA, ROE, ROICGNPX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GNPX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GNPX Yearly Profit, Operating, Gross MarginsGNPX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

4

2. Health

2.1 Basic Checks

GNPX has more shares outstanding than it did 1 year ago.
GNPX has more shares outstanding than it did 5 years ago.
GNPX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
GNPX Yearly Shares OutstandingGNPX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
GNPX Yearly Total Debt VS Total AssetsGNPX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

GNPX has an Altman-Z score of -67.51. This is a bad value and indicates that GNPX is not financially healthy and even has some risk of bankruptcy.
GNPX has a Altman-Z score of -67.51. This is amonst the worse of the industry: GNPX underperforms 94.96% of its industry peers.
There is no outstanding debt for GNPX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -67.51
ROIC/WACCN/A
WACCN/A
GNPX Yearly LT Debt VS Equity VS FCFGNPX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 0.83 indicates that GNPX may have some problems paying its short term obligations.
With a Current ratio value of 0.83, GNPX is not doing good in the industry: 89.37% of the companies in the same industry are doing better.
GNPX has a Quick Ratio of 0.83. This is a bad value and indicates that GNPX is not financially healthy enough and could expect problems in meeting its short term obligations.
GNPX has a worse Quick ratio (0.83) than 89.18% of its industry peers.
Industry RankSector Rank
Current Ratio 0.83
Quick Ratio 0.83
GNPX Yearly Current Assets VS Current LiabilitesGNPX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

GNPX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 70.08%, which is quite impressive.
EPS 1Y (TTM)70.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.95%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

GNPX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 36.77% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y85.94%
EPS Next 2Y36.77%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GNPX Yearly Revenue VS EstimatesGNPX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2028 2029 50M 100M 150M
GNPX Yearly EPS VS EstimatesGNPX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2020 2021 2022 2023 2024 2025 2026 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

GNPX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year GNPX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GNPX Price Earnings VS Forward Price EarningsGNPX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GNPX Per share dataGNPX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4 -5

4.3 Compensation for Growth

GNPX's earnings are expected to grow with 36.77% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.77%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GNPX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GENPREX INC

NASDAQ:GNPX (10/7/2025, 4:38:04 PM)

After market: 0.2049 +0 (+1.29%)

0.2023

0 (-0.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-11 2025-11-11/amc
Inst Owners1.74%
Inst Owner Change0%
Ins Owners0.21%
Ins Owner Change-0.72%
Market Cap8.68M
Analysts82.86
Price Target7.65 (3681.51%)
Short Float %12.37%
Short Ratio0.39
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-75.79%
Min EPS beat(2)-189.09%
Max EPS beat(2)37.52%
EPS beat(4)1
Avg EPS beat(4)-55.47%
Min EPS beat(4)-189.09%
Max EPS beat(4)37.52%
EPS beat(8)2
Avg EPS beat(8)-39.29%
EPS beat(12)4
Avg EPS beat(12)-26.12%
EPS beat(16)6
Avg EPS beat(16)-17.15%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.36
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-5.64
EYN/A
EPS(NY)-1.17
Fwd EYN/A
FCF(TTM)-0.4
FCFYN/A
OCF(TTM)-0.4
OCFYN/A
SpS0
BVpS0.04
TBVpS-0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -518.59%
ROE -1320.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-300.81%
ROA(5y)-201.57%
ROE(3y)-614.27%
ROE(5y)-390.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.83
Quick Ratio 0.83
Altman-Z -67.51
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)236.4%
Cap/Depr(5y)318.48%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)70.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.95%
EPS Next Y85.94%
EPS Next 2Y36.77%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y31.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y30.88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.68%
OCF growth 3YN/A
OCF growth 5YN/A